4 December 2018 - - US-based biopharmaceutical company Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) has closed an underwritten public offering of 18,602,941 shares of its common stock, including 2,426,470 shares of common stock sold pursuant to the underwriters' full exercise of their option to purchase additional shares, at a public offering price of USD 17.00 per share, the company said.

The gross proceeds from the offering to Acadia, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Acadia, are approximately USD 316.2m.

BofA Merrill Lynch, J.P. Morgan Securities LLC and Goldman Sachs and Co. LLC acted as the joint book-running managers for the offering.

Cowen and company, LLC acted as lead manager and Cantor Fitzgerald and Co., JMP Securities LLC and Needham and Company, LLC acted as co-managers for the offering.

Acadia is a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders.

The company has developed and is commercializing the first and only medicine approved for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.

In addition, Acadia has ongoing clinical development efforts in additional areas with significant unmet need, including dementia-related psychosis, schizophrenia inadequate response, schizophrenia-negative symptoms, major depressive disorder, and Rett syndrome.